Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Tuesday 19th September 2017 from 8.00am to 4.00pm (BST).

During this time our website performance may be temporarily affected. If you have any questions please use the feedback button available under our menu button. We apologise for any inconvenience this might cause and thank you for your patience.

Metabolomics for the early detection of cisplatin-induced nephrotoxicity

Author affiliations


Cisplatin, which is an inorganic molecule containing a platinum ion, is an antineoplastic agent that has been used to treat various solid tumors. However, its side effects include nephrotoxicity, neurotoxicity, bone marrow toxicity, gastrointestinal toxicity, and ototoxicity, which can limit its use. In this study, nephrotoxicity was caused by the intraperitoneal injection of cisplatin into rats, and then metabolome analysis was performed using gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS) to find plasma metabolite biomarker candidates that would facilitate the early detection of cisplatin-induced nephrotoxicity. As a result, chronological changes were detected in the plasma levels of cysteine–cystine and 3-hydroxy-butyrate in the GC/MS-based metabolomics study. In the LC/MS-based metabolomics study, 3 acylcarnitines and a phosphatidylethanolamine with C18:2–C18:2 were identified as potential plasma biomarkers of cisplatin-induced nephrotoxicity. The plasma levels of these 6 metabolites altered significantly after the administration of cisplatin, and these alterations occurred quicker than the equivalent changes in the plasma levels of creatinine and blood urea nitrogen, which are usually used as indicators of renal dysfunction. These results indicate that the abovementioned metabolites might be reliable biomarkers that would allow the earlier detection of cisplatin-induced nephrotoxicity and that metabolomics is a useful tool for discovering biomarkers that could be used to predict the side effects of cancer therapy.

Graphical abstract: Metabolomics for the early detection of cisplatin-induced nephrotoxicity

Back to tab navigation

Supplementary files

Publication details

The article was received on 14 Jun 2017, accepted on 23 Aug 2017 and first published on 29 Aug 2017

Article type: Paper
DOI: 10.1039/C7TX00171A
Citation: Toxicol. Res., 2017, Advance Article
  •   Request permissions

    Metabolomics for the early detection of cisplatin-induced nephrotoxicity

    T. Ezaki, S. Nishiumi, T. Azuma and M. Yoshida, Toxicol. Res., 2017, Advance Article , DOI: 10.1039/C7TX00171A

Search articles by author